Combined Intraperitoneal Paclitaxel and Systemic Chemotherapy for Patients with Massive Malignant Ascites Secondary to Pancreatic Cancer: A Report of Two Patients

Intern Med. 2023 Dec 4. doi: 10.2169/internalmedicine.2191-23. Online ahead of print.ABSTRACTThe prognosis of patients with peritoneal metastases from pancreatic cancer is poor, largely due to massive ascites, which precludes systemic treatment. Two patients with a poor performance status and malignant ascites were treated with cell-free and concentrated ascites reinfusion therapy followed by combined chemotherapy with intraperitoneal paclitaxel, intravenous gemcitabine, and nab-paclitaxel. These patients achieved a survival of 19 and 36 weeks with a relatively good quality of life. Combined intraperitoneal paclitaxel and systemic chemotherapy may provide effective palliative management for some patients with peritoneal metastases from pancreatic cancer.PMID:38044154 | DOI:10.2169/internalmedicine.2191-23

Source: Internal Medicine - December 3, 2023 Category: Internal Medicine Authors: Yoshiyuki Meguro Hironori Yamaguchi Hideki Sasanuma Kentaro Shimodaira Yuichi Aoki Takashi Chinen Kazue Morishima Hideyo Miyato Atsushi Miki Kazuhiro Endo Alan Kawarai Lefor Joji Kitayama Naohiro Sata Source Type: research